声门型 T2N0/Ⅱ期鳞状细胞癌放疗后的结果。
Outcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma.
机构信息
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Department of Radiation Oncology, American University of Beirut, Beirut, Lebanon.
出版信息
Head Neck. 2020 Oct;42(10):2791-2800. doi: 10.1002/hed.26308. Epub 2020 Jun 2.
BACKGROUND
We report outcomes for patients with T2N0M0 glottic squamous cell carcinoma (SCC) treated with radiation therapy (RT).
METHODS
Patients who received definitive RT for T2 glottic SCC from 2000 through 2013 were retrospectively reviewed.
RESULTS
One hundred and thirteen patients were analyzed (median follow-up time 91 months; 85 patients received three-dimensional conformal radiotherapy [3D-CRT] and 28 received intensity-modulated radiation therapy [IMRT]). Fractionation was conventional (58%) or altered (42%); 20 patients (18%) received concurrent chemotherapy. Five-year local control was 83% for the 3D-CRT vs 81% for the IMRT group (P = .76). The ultimate locoregional control at 5 years was 100% for IMRT vs 91% for 3D-CRT (P = .1). The 5-year overall survival (OS) was 78% for 3D-CRT vs 81% for IMRT (P = .83). On multivariate analysis, younger age was the only independent predictor of improved OS (P = .0002).
CONCLUSIONS
Oncologic and survival outcomes were excellent for patients with T2N0 glottic cancer. Patients treated with IMRT and 3D-CRT had no statistically significant differences in all investigated endpoints.
背景
我们报告了接受放射治疗（RT）的 T2N0M0 声门型鳞状细胞癌（SCC）患者的治疗结果。
方法
回顾性分析了 2000 年至 2013 年间接受 T2 声门 SCC 根治性 RT 的患者。
结果
对 113 例患者进行了分析（中位随访时间为 91 个月；85 例患者接受了三维适形放疗（3D-CRT），28 例患者接受了调强放疗（IMRT））。分割方式为常规（58%）或改变（42%）；20 例（18%）患者接受了同期化疗。3D-CRT 组的 5 年局部控制率为 83%，IMRT 组为 81%（P=0.76）。5 年最终局部区域控制率，IMRT 组为 100%，3D-CRT 组为 91%（P=0.1）。5 年总生存率（OS），3D-CRT 组为 78%，IMRT 组为 81%（P=0.83）。多因素分析显示，年龄较小是 OS 改善的唯一独立预测因素（P=0.0002）。
结论
对于 T2N0 声门癌患者，肿瘤学和生存结果均良好。接受 IMRT 和 3D-CRT 治疗的患者在所有研究终点均无统计学差异。
Zotero 插件